This study reveals a key mechanism underlying the limited efficacy of regorafenib following tyrosine kinase inhibitor (TKI) resistance, providing new biomarkers and therapeutic targets for precision medicine in hepatocellular carcinoma (HCC), with direct implications for optimizing clinical targeted therapies.
Literature Overview
The article titled 'ERBB3 blockade sensitizes hepatocellular carcinoma to regorafenib after first-line tyrosine kinase inhibitor resistance by inhibiting HIF1A-ABCB1 signaling,' published in Clinical and Molecular Hepatology, systematically investigates why hepatocellular carcinoma (HCC) responds poorly to second-line regorafenib after resistance develops to first-line tyrosine kinase inhibitors (TKIs) such as sorafenib or lenvatinib. Using a genome-wide CRISPR screen, the study identifies ERBB3 as a synthetic lethal target of regorafenib and reveals that it promotes drug efflux through activation of the HIF1A-ABCB1 signaling axis, leading to resistance. This finding offers a novel strategy to overcome resistance in sequential targeted therapy.Background Knowledge
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and most patients are diagnosed at an advanced stage with limited treatment options. First-line TKIs such as sorafenib and lenvatinib have low objective response rates (ORR), and the majority of patients eventually progress. Regorafenib is recommended in clinical guidelines as a second-line therapy after TKI resistance, yet its efficacy remains suboptimal, with a median progression-free survival (mPFS) of approximately 3.1–3.2 months and an ORR of only 11–13.6%. The core clinical challenge lies in the lack of effective predictive biomarkers and strategies to enhance drug sensitivity. Currently, research on ERBB3 in HCC is limited, and its feedback activation after TKI resistance and role in mediating drug efflux remain poorly understood. This study hypothesizes that tumor cells undergo intrinsic adaptive changes upon acquiring resistance, which may create a barrier to subsequent therapies. By conducting a genome-wide CRISPR screen, the authors systematically searched for genes exhibiting synthetic lethality with regorafenib, ultimately identifying ERBB3 as a critical resistance factor and a potential therapeutic target.
Research Methods and Experiments
The authors first established sorafenib-resistant (SR) and lenvatinib-resistant (LR) HCC cell lines and organoid models, confirming their resistant phenotypes and enhanced migratory capacity. Subsequently, they performed a genome-wide CRISPR-Cas9 knockout library screen in SR and LR cells to identify synthetic lethal interactions with regorafenib. Using the MAGeCK algorithm for data analysis, ERBB3 was identified as a co-lethal target of regorafenib. In both SR/LR cells and organoids, shRNA-mediated knockdown of ERBB3 significantly increased sensitivity to regorafenib, confirming the synthetic lethal relationship.
To elucidate the underlying mechanism, the authors conducted RNA-seq and pathway enrichment analyses, revealing significant activation of the ERBB3 signaling pathway in resistant cells. Gain- and loss-of-function experiments, combined with Western blotting, demonstrated that ERBB3 upregulates HIF1A expression via the PI3K/AKT pathway, not the MAPK/ERK pathway. Furthermore, promoter luciferase reporter and mutation assays confirmed that HIF1A directly binds to the ABCB1 promoter and enhances its transcription. Finally, using FITC-labeled regorafenib in drug efflux assays, the study visually demonstrated that high expression of ERBB3 or ABCB1 accelerates drug efflux, whereas their inhibition slows efflux and reduces intracellular drug clearance.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides important mechanistic insights and potential solutions for sequential targeted therapy in hepatocellular carcinoma. From a drug development perspective, ERBB3 and HIF1A emerge as novel intervention nodes, enabling the design of small-molecule inhibitors or antibody-based therapeutics. Moreover, as an effector molecule, inhibiting ABCB1 may exert broad-spectrum sensitizing effects. This discovery advances the field from empirical sequential therapy toward biomarker-guided precision medicine.
In terms of clinical monitoring, assessing ERBB3 expression levels could become a practical tool to guide regorafenib use, avoiding ineffective treatment in patients with high ERBB3 expression and conserving healthcare resources. Additionally, this mechanism may be applicable to other sequential TKI therapies and warrants validation in non-small cell lung cancer or colorectal cancer.
In the field of disease modeling, the SR/LR cell lines, organoids, and PDX models established in this study provide high-quality platforms for investigating acquired resistance mechanisms. These models can be leveraged in future high-throughput screens to identify additional synthetic lethal targets or sensitizing compounds.
Conclusion
This study systematically uncovers the underlying mechanism for poor response to regorafenib in hepatocellular carcinoma following first-line TKI resistance—the feedback activation of the ERBB3-HIF1A-ABCB1 signaling axis leading to enhanced drug efflux. This finding not only explains the fundamental reason for limited clinical efficacy but also proposes a dual strategy: first, using ERBB3 expression levels as a biomarker for patient selection to enable precision therapy; and second, combining regorafenib with ERBB3-targeted agents (e.g., Seribantumab) to reverse resistance and improve outcomes. From bench to bedside, this research provides a complete pathway from mechanistic understanding to therapeutic intervention in sequential HCC treatment, with the potential to significantly improve prognosis for patients with advanced HCC. Moving forward, validating the predictive power of this pathway in larger patient cohorts and advancing combination therapies into clinical trials will be critical next steps in translational medicine. This work reinforces the concept of 'post-resistance state' as a dynamic therapeutic target and offers a paradigm applicable to sequential therapy in other solid tumors.
